Rewriting the playbook on rheumatoid arthritis—Immorta Bio’s breakthrough anti‑aging stem‑cell therapy shows dramatic promise in preclinical trials.
Their personalized pMSCs (patient‑derived mesenchymal stem cells) not only outperformed conventional bone‑marrow and umbilical‑cord sources, but also demonstrated superior effectiveness at reducing RA symptoms in lab models—marking a major leap forward in regenerative medicine and chronic inflammatory disease treatment.
Find out more in our latest podcast episode:
Other Immorta Bio articles you might be interested in:
For more info visit: https://www.immortabio.com/
